Greg Roloff
@RoloffGreg
Followers
638
Following
5K
Media
22
Statuses
385
Academic hematologist interested in leukemia, cell/gene therapy, transplant. Buffalo born. Views, typos, and grammatical errors = mine
Chicago, IL
Joined June 2020
Topline results studying brexu-cel in relapsed B-ALL, now out @JCO_ASCO. My thanks to @LoriMuffly and partners from 30+ centers driven to answer ?s in a rare disease space. More to come. @bshah @MoffittNews @UChicagoHemOnc
https://t.co/qTw2NQgDKP
ascopubs.org
PURPOSEOn the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration...
3
10
50
Just out in the Journal of Clinical Oncology! @JCO_ASCO A paradigm changing paper on MGUS and Smoldering Myeloma @FrancescoMaura4 And it’s Open Access!! https://t.co/XgIW0EyrC9 KEY FINDINGS: 1) We identify for the first time myeloma defining genomic events to differentiate
7
64
203
On this morning, a reminder that Bert Vogelstein demonstrated cancer caused by sequential accumulation of gene mutations, described role of TP53 mutations in cancer, outlined hereditary and somatic causes of colorectal cancer, developed digital PCR and field of liquid biopsy...
0
3
32
Statins Enhance the Efficacy of Pegylated Interferon-α2 in Philadelphia-Negative Chronic Myeloproliferative Neoplasms
ashpublications.org
Key Points. Statins enhance treatment responses in IFN-treated MPN patients, allowing for lower IFN doses and faster complete hematologic response.A dose-r
0
1
1
Thanks again @RoloffGreg for fantastic & thought provoking commentary piece. Still so much to learn about tMN post-CAR… https://t.co/ymz9QXCOTu
@uclcancer @maeveannoreilly @FESillito
Thrilled to share our latest study on secondary myeloid malignancies after CAR-T cell therapy led by Dr Francesca Sillito @uclh @drclaireroddie @Capt__Kirkwood @Haematologica
https://t.co/LVpBMVrdYG
1
7
18
Thrilled to share our latest study on secondary myeloid malignancies after CAR-T cell therapy led by Dr Francesca Sillito @uclh @drclaireroddie @Capt__Kirkwood @Haematologica
https://t.co/LVpBMVrdYG
3
10
26
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
ashpublications.org
Key PointsMatched allogeneic donor CD19 CAR-T therapy (CAR-DLI) is safe and effective for relapsed adult B-ALL but only after lymphodepletion.Repeat CAR-DL
0
5
19
Our deeper dive on @BMTCTN 1506 aka Morpho trial: FLT3-ITD/NPM1 co mutants with residual MRD uniquely benefit from #gilteratinib maintenance. FLT3-ITD/NPM1 co-mutation status may inform #alloHCT conditioning intensity decision #bmtsm #leusm
ashpublications.org
Key PointsMAC was no more effective than RIC in eradicating FLT3-ITD MRD.NPM1 comutation was associated with the largest magnitude of relapse-free survival
1
11
59
We are honored to congratulate @DrWendyStock of @UCCancerCenter for her 2025 Giants of Cancer Care Leukemia induction! #GiantsCC25 #leusm
0
7
23
Obecabtagene Autoleucel Emerges as an Avenue for Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
ashpublications.org
Roddie C, Sandhu KS, Tholouli E, . Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391(23):2219-2230. PubMed
0
1
11
More great research coming from our @UCHemOncFellows!! Drs. Shaw, Cannova, Johnston, and Madero-Marroquin in @BloodAdvances ( https://t.co/83n2XzVX4X and https://t.co/XfH4Nmgw4W) & Dr. Cannova in @OncologyAdvance ( https://t.co/6vSFrfAJkY)!!
ashpublications.org
1
4
11
WATCH: @DanielOlsonMD discusses the potential of TIL therapy, a groundbreaking cancer treatment that transformed cancer patient Alla Pinzour's life. @UChicagoMed is proud to be the first in the Midwest to offer this innovative therapy. @UChicagoHemOnc
https://t.co/3Qs3Eut8Fu
0
3
8
Excellent OpEd by @AldConway @NewDayConway on need to end the fiscal recklessness on full, daily display in Chicago by @ChicagosMayor Brandon Johnson. Borrowing $830 million at a cost of more than $2 billion is insane. Read it & contact your alderman.
chicagotribune.com
The size and the schedule for an additional $830 million in debt are reckless and could be more responsibly structured by Mayor Brandon Johnson.
18
37
213
Congratulations to our Section Chief, Dr. @SoniSmithMD new electee to the @ASCO Board of Directors as the Designated Medical Oncologist!! We see her dedicated & positive leadership daily & know how deserving she is of this honor! More from ASCO at
2
5
37
For the seventh time, University of Chicago Medical Center has been named a Top Teaching Hospital by the @LeapfrogGroup for its high standards for patient safety and quality care. Read more: https://t.co/oRnKXszsBz
0
2
9
New annual tradition at ASH 🩸 💪
Another @ASH_hematology #ASH24 highlight: making new friends from around the world while lifting heavy weights with @DrHelenOram and @RoloffGreg Shoutout to @mjbrunns and @sghmd for starting this tradition! Missed y’all!
1
1
12
Is there any pumping of iron happening at ASH this year @sghmd @rmistry91 ? If so I want in 💪
3
0
11
Obe-Cel Approval Expands CAR T-Cell Therapy Options in Relapsed/Refractory ALL @LoriMuffly @StanfordMed @MDAndersonNews @RoloffGreg @UChicagoHemOnc #leusm #oncology #MedEd #MedTwitter
https://t.co/ymlXANEjRQ
onclive.com
Hematologic oncologists offer their perspective on the current and potential future standing of CAR T-cell therapies in the relapsed/refractory ALL treatment landscape.
0
3
7